ASCO 2026 Preview: LBA Oral Abstract Session-Landmark Results from the Pivotal Study of Asandeutertinib vs. Osimertinib as First-Line Treatment for EGFR-Mutated NSCLC with Brain Metastases
TYK Medicines will present the research progress and results of 5 innovative drug projects at the 2026 Annual Meeting of American Association for Cancer Research (AACR 2026)
